Tagside effects

Primary care clinicians’ experiences prescribing HIV PrEP at a specialized community health centre

By J Pope
In Gay Lesbian & Bisexual Health, HIV
2 Min Read
P

Journal of the International AIDS Society 2016, 19:21165 Abstract: Introduction: An estimated 1.2 million Americans have indications for using antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV acquisition. For many of these at-risk individuals, the best opportunity to learn about and receive PrEP will be during routine visits to their generalist primary care clinicians. However, few...

Read onRead later

Mirena IUD effective for seven years: new study

By J Pope
In Contraception
1 Min Read
M

Dr Jennifer Gunter, September 10 2016 The Mirena intrauterine system (IUS), the IUD with the hormone levonorgestrel, is a highly effective method of contraception currently approved for five years. Some data suggests that it probably good for six years, but a new study tells us with a good degree of confidence that the Mirena is safe and effective for seven years.  The study was funded by UNDP/...

Read onRead later

On World Hepatitis Day it’s time to talk about HIV and hepatitis C

By J Pope
In Hepatitis, HIV
1 Min Read
O

National Association of people with HIV Australia, July 28 2016 On World Hepatitis Day, the National Association of People with HIV Australia (NAPWHA), the Australian Federation of AIDS Organisations (AFAO), the Kirby Institute and Hepatitis Australia are raising awareness about HIV and hepatitis C (HCV) co-infection. An estimated 3,000 Australians are living both with HIV and HCV. HCV is more...

Read onRead later

New Treatments for Hepatitis C: the facts

By J Pope
In Hepatitis
1 Min Read
N

Hepatitis NSW, 2016 This is a really exciting time if you live in Australia and have hep C. The Federal government has announced that new direct acting antiviral (DAA) treatment drugs will be free and available to you from 1 March 2016. The new treatments are: Harvoni® (sofosbuvir/ledipasvir) two drugs combined in each pill Sovaldi® and Daklinza® (sofosbuvir and daclatasvir) separate pills, taken...

Read onRead later

New PrEP studies will be a challenge, statisticians warn

By J Pope
In HIV
1 Min Read
N

nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...

Read onRead later

Your sidebar area is currently empty. Hurry up and add some widgets.